Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract …
SH Lob, DD DePestel, CA DeRyke… - Open Forum …, 2021 - academic.oup.com
Background Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa,
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
[PDF][PDF] Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory …
SH Lob, DD DePestel, CA DeRyke, KM Kazmierczak… - 2021 - pdfs.semanticscholar.org
Background. Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa,
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
[HTML][HTML] Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With …
SH Lob, DD DePestel, CA DeRyke… - Open Forum …, 2021 - ncbi.nlm.nih.gov
Background Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa,
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract …
SH Lob, DD DePestel, CA DeRyke… - Open forum …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa,
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract …
SH Lob, DD DePestel, CA DeRyke… - Open Forum Infectious …, 2021 - go.gale.com
Background. Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa,
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract …
SH Lob, DD DePestel, CA DeRyke… - Open Forum …, 2021 - europepmc.org
Background Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa,
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
[PDF][PDF] Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory …
SH Lob, DD DePestel, CA DeRyke… - Open Forum …, 2021 - academic.oup.com
Background Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa,
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract …
SH Lob, DD DePestel, CA DeRyke… - Open Forum …, 2021 - search.ebscohost.com
Background Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa,
which are more common in patients with lower respiratory tract infections (LRTIs) and in …
which are more common in patients with lower respiratory tract infections (LRTIs) and in …